Navigation Links
PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
Date:9/21/2012

LEIPZIG, Germany and NES-ZIONA, Israel, Sept. 21, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that data from the company's Phase II trial of hGH-CTP, its long acting human growth hormone, in growth hormone deficient adults will be presented at ESPE 2012, the 51st Annual Meeting of the European Society for Paediatric Endocrinology. 

The previously reported data confirmed that a single weekly injection of hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone from the current standard of one injection per day to a single weekly injection.  In this trial, hGH-CTP demonstrated a good safety and tolerability profile.  In addition, the study showed that only 50-65% of the cumulative weekly dose of conventional human growth hormone was required for the majority of the patients to remain within the normal range of IGF-1, a key biomarker of growth hormone activity.  The safety profile of hGH-CTP in this trial was further enhanced by the finding that it did not cause excessive IGF-1 levels in patients, nor was any IGF-I accumulation observed.

The positive Phase II data in adults were instrumental in PROLOR's decision to proceed with a Phase II hGH-CTP trial in growth hormone deficient children that is currently enrolling patients.  The pediatric Phase II trial is a randomized, open-label, dose-finding study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamic properties of hGH-CTP injected weekly in children with growth hormone deficiency.  The trial is comparing the 12-month growth velocity of children receiving hGH-CTP injected once weekly with those receiving commercially available hGH injected daily.

"Growth hormone replacement therapy may enable a growth hormone deficient child to reach a normal height, but it currently involves daily dosing that may total more than 3,000 injections before the child reaches t
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
2. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
3. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
4. Air Products to Feature Medical and Industrial Grade Gas Solutions for Pharma, Biotech, and Life Science Applications at Mid-Atlantic Bio Conference
5. Biotech Executive Salaries Continue to Rise Despite Weak Economy
6. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
7. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
8. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
9. Germany Prioritizes Medical Biotechnology with New Initiatives
10. Why Texas is #1 in Business: Local BioTech Company Expands
11. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... November 26, 2014 Biomedical devices that ... systems to enable 3D manufacture at the micro-nanoscale, and ... are among finalists in nine categories for the ... are sponsored by SPIE, the international society for ... , Winners will be announced by industry leaders on ...
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... Bifluoride Industry” is a professional and in-depth research ... Ammonium Bifluoride information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... On January, 14, 2015, UMBC’s Biotechnology ... science community to the UMBC campus for a discussion ... Protein Society, will take place from 9 a.m. to ... Through discussion, presentations and workshops, the free symposium will ... role in the industry and the future of protein ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... ... for 87-Acre R&D/Manufacturing Facility , ... Philadelphia, Pa. (Vocus) September 8, 2009 -- BPG Properties, Ltd. ... 2750 Morris Road , a 705,000 square foot highly specialized research and development/manufacturing facility ...
... PriceSpective, a value strategy consultancy that provides ... pleased to announce that it has hired two senior experts ... President, and Sophie Murdoch, as a Director, will help further ... offerings. , , Colasante, who brings 20 ...
... , INCLINE VILLAGE, Nev., Sept. 8 ... announced revenue guidance for the third quarter ended September 30, ... for the third quarter of 2008. Royalty revenues are based ... $1.6 million for Synagis(R), which is marketed by MedImmune. When ...
Cached Biology Technology:BPG Properties, Ltd. Announces 2750 Morris Road in Lansdale, Pennsylvania is for Sale 2BPG Properties, Ltd. Announces 2750 Morris Road in Lansdale, Pennsylvania is for Sale 3PriceSpective Appoints Colasante as a Vice President and Murdoch as a Director 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... from the United Kingdom, the Energy Department,s National Renewable ... recently published a paper describing a novel cellulose-degrading enzyme ... commonly known as the gribble. Gribbles are ... to produce their own enzymes instead of using symbiotic ...
... expecting a very large "dead zone" in the Gulf ... in the Chesapeake Bay this year, based on several ... of Michigan, Louisiana State University, and the Louisiana ... of Mexico hypoxic "dead" zone will be between 7,286 ...
... Joshua Obar, Ph.D., Department of Immunology and Infectious ... 2013 ICAAC Young Investigator Award for his research on ... to infection. Obar earned his B.A. in ... on to complete his Ph.D. in Microbiology and Immunology ...
Cached Biology News:Novel enzyme from tiny gribble could prove a boon for biofuels research 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4The American Society for Microbiology honors Joshua Obar 2
...
... Application: Pyronin Y is most widely ... to selectively and differentially stain nucleic ... a dichromatic dye solution, Pyronin Y ... stains DNA green. Chem ...
... kit is designed for the fast and ... plasmids at any position (for the generation ... cassette is designed to allow neomycin / ... It combines a prokaryotic promoter (gb2) for ...
... first instrument to offer true walk-away automation of ... isolate cells by either positive or negative selection, ... samples at one time. RoboSep is easily controlled ... user interface makes it simple and fast to ...
Biology Products: